Literature DB >> 3814487

Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis.

S C Darby, R Doll, S K Gill, P G Smith.   

Abstract

Mortality up to 1 January 1983 has been studied in 14,106 patients with ankylosing spondylitis given a single course of X-ray treatment during 1935-54. For neoplasms other than leukaemia or colon cancer, mortality was 28% greater than that of members of the general population of England and Wales, and this increase is likely to have been a direct consequence of the treatment. The proportional increase reached a maximum of 71% between 10.0 and 12.4 years after irradiation and then declined. There was only a 7% increase in mortality from these tumours more than 25.0 years after irradiation and only for cancer of the oesophagus was the relative risk significantly raised in this period. Neither the magnitude of the relative risk, nor its temporal pattern following treatment, were greatly influenced by the age of the patient at first treatment. For leukaemia there was a threefold increase in mortality that is also likely to have been due to the radiotherapy. The relative risk was at its highest between 2.5 and 4.9 years after the treatment and then declined, but the increase did not disappear completely, and the risk was still nearly twice that of the general population more than 25.0 years after treatment. There was some evidence that the risks of acute myeloid, acute lymphatic, and chronic myeloid leukaemia were all increased, but no evidence of any increase in chronic lymphatic leukaemia. The relative risk appeared to be greatest for acute myeloid leukaemia. For colon cancer, which is associated with spondylitis through a common association with ulcerative colitis, mortality was increased by 30%. For non-neoplastic conditions there was a 51% increase in mortality that was likely to be associated with the disease itself rather than its treatment. The increase was apparent for a wide range of diseases and was not confined to diseases that have been associated clinically with ankylosing spondylitis.

Entities:  

Mesh:

Year:  1987        PMID: 3814487      PMCID: PMC2002095          DOI: 10.1038/bjc.1987.35

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  Adult leukaemia; trends in mortality in relation to aetiology.

Authors:  W M COURT BROWN; R DOLL
Journal:  Br Med J       Date:  1959-04-25

2.  Cancer mortality among patients with ankylosing spondylitis not given X-ray therapy.

Authors:  P G Smith; R Doll; E P Radford
Journal:  Br J Radiol       Date:  1977-10       Impact factor: 3.039

3.  Mortality among patients with ankylosing spondylitis not given X-ray therapy.

Authors:  E P Radford; R Doll; P G Smith
Journal:  N Engl J Med       Date:  1977-09-15       Impact factor: 91.245

4.  The value of subtyping in studies of irradiation and human leukaemia.

Authors:  S C Darby
Journal:  Leuk Res       Date:  1985       Impact factor: 3.156

5.  Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis.

Authors:  W M Brown; R Doll
Journal:  Br Med J       Date:  1965-12-04

6.  Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries.

Authors:  J D Boice; N E Day; A Andersen; L A Brinton; R Brown; N W Choi; E A Clarke; M P Coleman; R E Curtis; J T Flannery
Journal:  J Natl Cancer Inst       Date:  1985-05       Impact factor: 13.506

7.  A parallel analysis of cancer mortality among atomic bomb survivors and patients with ankylosing spondylitis given X-ray therapy.

Authors:  S C Darby; E Nakashima; H Kato
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

8.  Mortality among patients with ankylosing spondylitis after a single treatment course with x rays.

Authors:  P G Smith; R Doll
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-13
  8 in total
  53 in total

Review 1.  Hormesis, an update of the present position.

Authors:  Lennart Johansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-26       Impact factor: 9.236

2.  Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Authors:  Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

3.  Epidemiological designs in radioepidemiological research.

Authors:  E Cardis; J Estève
Journal:  Soz Praventivmed       Date:  1991

4.  Projecting radiation-induced cancer risks across time and populations.

Authors:  C R Muirhead
Journal:  Soz Praventivmed       Date:  1991

5.  Lessons of Chernobyl.

Authors:  S C Darby; G K Reeves
Journal:  BMJ       Date:  1991-11-30

6.  On the use of combinatorial antibody libraries to clone the "fossil record" of an individual's immune response.

Authors:  R A Lerner; C F Barbas; A S Kang; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

Review 7.  Cardiac side effects of conventional and particle radiotherapy in cancer patients.

Authors:  A Wittig; R Engenhart-Cabillic
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 8.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

9.  Insights from radiation treatment for benign disease.

Authors:  N M Bleehen
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-29

10.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.

Authors:  P Simmonds; L Q Zhang; F McOmish; P Balfe; C A Ludlam; A J Brown
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.